Literature DB >> 14625308

Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling.

Christian Kollewe1, Anne-Christin Mackensen, Detlef Neumann, Johannes Knop, Ping Cao, Shyun Li, Holger Wesche, Michael U Martin.   

Abstract

The interleukin-1 receptor-associated kinase 1 (IRAK-1) is an important adapter in the signaling complex of the Toll/interleukin-1 (IL-1) receptor family. Formation of the signaling IL-1 receptor complex results in the activation and hyperphosphorylation of IRAK-1, which leads to a pronounced shift of its apparent molecular mass in gel electrophoresis. Presently, the individual residues phosphorylated in IRAK-1 and the consequences for IRAK-1 function are unknown. We define sequential phosphorylation steps in IRAK-1, which are, in vitro, autophosphorylation. First, IRAK-1 is phosphorylated at Thr209. By fluorescence energy transfer experiments, we demonstrate that Thr209 phosphorylation results in a conformational change of the kinase domain, permitting further phosphorylations to take place. Substitution of Thr209 by alanine results in a kinase-inactive IRAK-1. Second, Thr387 in the activation loop is phosphorylated, leading to full enzymatic activity. Third, IRAK-1 autophosphorylates several times in the proline-, serine-, and threonine-rich ProST region between the N-terminal death domain and kinase domain. Hyperphosphorylation of this region leads to dissociation of IRAK-1 from the upstream adapters MyD88 and Tollip but leaves its interaction with the downstream adapter TRAF6 unaffected. This identifies IRAK-1 as a novel type of adapter protein, which employs its own kinase activity to introduce negative charges adjacent to the protein interaction domain, which anchors IRAK-1 at the active receptor complex. Thus, IRAK-1 regulates its own availability as an adapter molecule by sequential autophosphorylation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14625308     DOI: 10.1074/jbc.M309251200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  83 in total

Review 1.  Regulations and roles of the interleukin-1 receptor associated kinases (IRAKs) in innate and adaptive immunity.

Authors:  Lu Gan; Liwu Li
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 2.  The involvement of the interleukin-1 receptor-associated kinases (IRAKs) in cellular signaling networks controlling inflammation.

Authors:  Lorna Ringwood; Liwu Li
Journal:  Cytokine       Date:  2008-01-30       Impact factor: 3.861

3.  Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus.

Authors:  Chaim O Jacob; Jiankun Zhu; Don L Armstrong; Mei Yan; Jie Han; Xin J Zhou; James A Thomas; Andreas Reiff; Barry L Myones; Joshua O Ojwang; Kenneth M Kaufman; Marisa Klein-Gitelman; Deborah McCurdy; Linda Wagner-Weiner; Earl Silverman; Julie Ziegler; Jennifer A Kelly; Joan T Merrill; John B Harley; Rosalind Ramsey-Goldman; Luis M Vila; Sang-Cheol Bae; Timothy J Vyse; Gary S Gilkeson; Patrick M Gaffney; Kathy L Moser; Carl D Langefeld; Raphael Zidovetzki; Chandra Mohan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-27       Impact factor: 11.205

4.  Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14+ Monocytes.

Authors:  Joe M Horvatinovich; Elizabeth W Grogan; Marcus Norris; Alexander Steinkasserer; Henrique Lemos; Andrew L Mellor; Irina Y Tcherepanova; Charles A Nicolette; Mark A DeBenedette
Journal:  J Immunol       Date:  2017-02-13       Impact factor: 5.422

5.  Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.

Authors:  Zhaoyang Li; Kenisha Younger; Ronald Gartenhaus; Ann Mary Joseph; Fang Hu; Maria R Baer; Patrick Brown; Eduardo Davila
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

6.  Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model.

Authors:  K Takashima; N Matsunaga; M Yoshimatsu; K Hazeki; T Kaisho; M Uekata; O Hazeki; S Akira; Y Iizawa; M Ii
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

7.  The CATERPILLER protein monarch-1 is an antagonist of toll-like receptor-, tumor necrosis factor alpha-, and Mycobacterium tuberculosis-induced pro-inflammatory signals.

Authors:  Kristi L Williams; John D Lich; Joseph A Duncan; William Reed; Prasad Rallabhandi; Christopher Moore; Sherry Kurtz; V McNeil Coffield; Mary A Accavitti-Loper; Lishan Su; Stefanie N Vogel; Miriam Braunstein; Jenny P-Y Ting
Journal:  J Biol Chem       Date:  2005-10-03       Impact factor: 5.157

8.  An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4.

Authors:  Precious G Motshwene; Martin C Moncrieffe; J Günter Grossmann; Cheng Kao; Murali Ayaluru; Alan M Sandercock; Carol V Robinson; Eicke Latz; Nicholas J Gay
Journal:  J Biol Chem       Date:  2009-07-10       Impact factor: 5.157

9.  Association of interleukin-1 receptor-associated kinase (IRAK1) gene polymorphisms (rs3027898, rs1059702) with systemic lupus erythematosus in a Chinese Han population.

Authors:  Yu Zhai; Ke Xu; Rui-Xue Leng; Han Cen; Wei Wang; Yan Zhu; Mo Zhou; Chen-Chen Feng; Dong-Qing Ye
Journal:  Inflamm Res       Date:  2013-02-23       Impact factor: 4.575

10.  In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells.

Authors:  Tanzilya Khayrullina; Jui-Hung Yen; Huie Jing; Doina Ganea
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.